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Abstract
Background: Statistical analysis plans describe the planned data management and analysis for
clinical trials. This supports transparent reporting and interpretation of clinical trial results.
This paper reports the statistical analysis plan for the RESOLVE clinical trial. The RESOLVE trial
assigned participants with chronic low back pain to graded sensory-motor precision training or
sham-control.
Results: We report the planned data management and analysis for the primary and secondary
outcomes. The primary outcome is pain intensity at 18-weeks post randomization. We will use
mixed-effects models to analyze the primary and secondary outcomes by intention-to-treat.

Corresponding author at: Centre for Pain IMPACT, Neuroscience Research Australia, 139 Barker St, Randwick, 2031, Sydney, Australia.
E-mail: m.bagg@neura.edu.au (M.K. Bagg).
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We will report adverse effects in full. We also describe analyses if there is non-adherence to
the interventions, data management procedures, and our planned reporting of results.
Conclusion: This statistical analysis plan will minimize the potential for bias in the analysis and
reporting of results from the RESOLVE trial.
Trial registration: ACTRN12615000610538
(https://www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=368619).
© 2020 Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia. Published by Elsevier
Editora Ltda. All rights reserved.

Introduction
Background and rationale
Low back pain is a burdensome and disabling health
condition.1,2 People who experience low back pain for longer
than three months have a low chance of recovery and
experience substantial functional and ﬁnancial difﬁculty.3---10
Results of clinical trials of contemporary interventions indicate that, on average, people with persistent low back
pain experience small to no beneﬁt, compared to control.
Accordingly, there is an urgent need to develop more effective interventions.
Recent progress in understanding the role of the central
nervous system (CNS) in the low back pain experience bears
promise for the development of new treatment approaches.
Accumulating data indicate that people with persistent
low back pain have differences in CNS structure, function,
and biochemistry; compared to people without pain.11---20
Research has demonstrated that these differences may be
related to aspects of the low back pain experience.21---23
Interventions designed to target the CNS (termed herein,
psychophysical interventions) have been developed and
tested in a number of small studies.24---27 Further research
has combined these new interventions with traditional
interventions directed towards functioning of the back, or
psychological aspects of the pain experience. These data
suggest that there may be additional beneﬁt from a combined approach.28---32 Work is underway to evaluate these
treatment programs in adequately powered, prospectively
registered, randomized controlled trials.33---35
The aim of the RESOLVE Trial is to evaluate the effectiveness of a psychophysical-traditional intervention (graded
sensory-motor precision training) compared to a sham intervention for reducing pain intensity for people with persistent
low back pain at 18-weeks post-randomization. This statistical analysis plan reports the planned analyses of primary
and secondary outcomes.

Methods
Trial design
The RESOLVE Trial is a two-group, parallel, randomized
clinical trial with 1:1 allocation. Participants and outcome assessors are blinded to group allocation and study

hypotheses.33 Ethical approval was granted by the University of New South Wales Human Research Ethics Committee
(HC15357). This statistical analysis plan follows the recommendations of the Guidelines for the Content of Statistical
Analysis Plans in Clinical Trials.36

Eligibility
The eligibility criteria are described brieﬂy here and comprehensively in the protocol.33 We included people with pain
(intensity rated at least 3/10) between the 12th rib and buttock crease, with or without leg pain, that had persisted for
at least 12 weeks. Participants must have been aged 18---70,
ﬂuent in English, able to access the internet, and have a
trusted person to assist with the intervention at home. We
excluded people with known or suspected serious spinal
pathology, nerve root compromise, or contraindications to
physical activity, transcranial direct current stimulation,
cranial electrical stimulation, low-intensity laser therapy
or short-wave diathermy. We excluded people who were
pregnant or had given birth less than 6 months previously,
undergone spinal surgery less than 12 months previously,
scheduled major surgery during the next 12 months, or selfidentiﬁed [an] uncontrolled mental health condition(s) that
they felt may impact participation.

Interventions
The interventions are described brieﬂy here and comprehensively in the protocol.33 Graded sensory-motor precision
training comprised pain neuroscience education (2 sessions) followed by contiguous sensory precision training and
graded movement imagery (3 sessions) and concluded with
graded precision-focused and feedback-enriched, functional
movement (7 sessions). There were twelve 60-min clinical
sessions, scheduled approximately weekly, over a period
of 12---18 weeks; and, daily 30-min sessions at home, concluding at session 12. The sham intervention was matched
for time and clinician interaction and comprised passive
discussion of the participant’s back pain experience followed by sham transcranial direct current stimulation,
sham cranial electrical stimulation (at home only), detuned low-intensity laser therapy, and de-tuned short-wave
diathermy.
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CONSORT ﬂow diagram (shell, greyscale).

Randomization
A scientist with no involvement in the conduct of the trial
used a blocked randomization model to generate the allocation sequence. The allocations were printed and placed in
276 sealed, opaque, sequentially numbered envelopes.33

Outcome assessments and withdrawal
Outcomes were measured at baseline and 18, 26, and
52-weeks post-randomization. Intervention credibility was
measured at baseline and 2-weeks post-randomization. We
did not specify interim analyses in the trial protocol.33
We determined during the trial that we had sufﬁcient
funding to complete recruitment and collect the primary
endpoint at 18-weeks for all participants, after which we
would close the trial. We collected the primary endpoint for

participant ID276 on 28th November 2019 and initiated the
ﬁnal collection of outcome data for all remaining participants that had not completed follow-up (deﬁned as receipt
of outcome data for the 52-week time point). We contacted
n = 45 participants to provide their 52-week time point data
early and n = 34 participants to provide their 26-week time
point data early. This latter group of participants did not
provide outcome data for the 52-week time point.
We will use an adapted CONSORT ﬂow diagram37 and
accompanying table to describe the movement of participants through the study. A shell of the adapted ﬂow diagram
is shown in Fig. 1. Participants may withdraw from the trial
intervention, fail to provide follow up data, or both. Additionally, participants may withdraw their consent from the
trial completely. We will report these items in the ﬂow diagram and a separate table (Supplemental Material Table
A1).
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Sample size
The required sample size is n = 276 participants to have
at least 80% power to detect a minimal clinically important difference38 of 1-point (SD 2.0) in pain intensity (0---10
numeric rating scale, NRS), between levels of intervention,
at 18-weeks post-randomization. We calculated the sample
size for an interaction between time (four observations) and
levels of intervention, using an estimated inter-observation
correlation of base 0.6 with decay rate 0.1 and adjusted for
up to 15% loss to follow up.33,39

Data integrity and missing data
We collected data from participants ID001-070 in hard copy
format. These data will be entered in duplicate. Discrepancies will be resolved by consensus, with recourse to the
Chief Investigator as required. We collected data from participants ID071-276 using a custom-developed on-line system.
These data do not require entry. We will inspect the range,
central tendency, and variance of all variables. We will note
implausible values and make appropriate replacements in
the cleaned dataset.
We have monitored the proportion of missing data during the trial. We assume that missing observations do so at
random. The mixed-effects models that we will use for the
analysis of primary and secondary outcomes are robust to
data missing at random.

Analytic principles
General considerations
We will conduct the analyses respecting these principles:
* all participants will be analyzed in the group to which
they were allocated (intention-to-treat40 )
* all treatment effect estimates will be reported along
with their associated 95% conﬁdence intervals
* all statistical tests will be 2-sided with a nominal alpha
level of .05
* P values will not be adjusted for multiplicity. However, the outcomes are clearly categorized by degree of
importance33 and no subgroup analysis will be performed.
* the null hypothesis for each outcome is that there is no
difference between the intervention groups. Whereas, the
alternative hypothesis is that graded sensory-motor precision training differs from the control intervention.
* all analyses will be performed using Stata41 and R.42---44

Outcome deﬁnitions
Primary outcome
The primary outcome is pain intensity, deﬁned as average
pain intensity in the past week, assessed using a subjectrated 11-point NRS at 18-weeks post-randomization.33 The
NRS is a continuous measure that ranges from 0 (no pain) to
10 (worst pain imaginable).45

Secondary outcomes
The secondary outcomes are function, quality of life
(QoL), recovery, adverse effects, serious adverse effects,
global perceived effect (GPE), and intervention credibility. Measurement properties are described in the protocol.33
Function is assessed using the Roland-Morris Disability Questionnaire (RMDQ).46 QoL is assessed using the EQ-5D-5L.47,48
Recovery is deﬁned as recovery from back pain at 26-weeks
post-randomization. We will consider a participant recovered at 26-weeks when the outcome score for pain intensity
(in the past week) is either 0 or 1 on the 11-point NRS at both
18- and 26-weeks.49---51 We are collecting data on adverse
effects using passive capture,44 throughout the trial period
(0−52wks for each participant).33 We will report adverse
effects using the United States Food and Drug Administration (FDA) deﬁnitions,52 wherein ‘any untoward medical
occurrence associated with the intervention, whether or not
considered related to the intervention’(edited) constitutes
an adverse effect and a serious adverse effect is considered
to have occurred when any of the following sequelae occur
or medical intervention is required to prevent occurrence:
‘death, threat to life, in-patient hospitalization or prolongation of existing hospitalization, a persistent or signiﬁcant
incapacity or substantial disruption of the ability to conduct
normal life functions’. The GPE of intervention is assessed
using the Global Back Recovery Scale (GBRS).53 Intervention
credibility is assessed using the Credibility and Expectancy
Questionnaire (CEQ).54

Compliance with the intervention
Compliance was assessed by recording the attendance of
participants at each treatment session. We will consider
compliance as a continuous variable, deﬁned as the number
of treatment sessions attended, and as a binary variable,
deﬁned as attendance of greater than or equal to eight
treatment sessions (75% of the intervention). We will present
frequency distributions for both groups to describe the
proportion of participants that attended each intervention
session. We will also present the proportion of participants
in either group that attended greater than or equal to eight
treatment sessions.

Analysis
Baseline description
We will use the data items depicted in Table 1 to describe
the sample and each group at baseline. We will use the frequency and percentage of observations to summarize binary
variables, the mean and standard deviation to summarize
normally distributed continuous variables and the median
and inter-quartile range otherwise.
Primary outcome
We will use a mixed-effects model to estimate the effect
of allocation to intervention group on the primary outcome;
pain intensity at 18-weeks post randomization. Mixed-effect
models are recommended for estimating treatment effects
at speciﬁc time-points in clinical trials.55---57 We will model
intervention group as a binary variable and time as a cate-
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Baseline Characteristics (shell).

Characteristic

Age1
Biological sex (female)2
Duration current episode LBP1
Number of previous episodes LBP3
Number of other areas of pain3
Work absence or reduced hours2
Compensation claimed2
Highest education level
High school year 102
High school year 122
Vocational certiﬁcate2
Diploma2
Bachelor degree or higher2
Pain intensity in the past week1
Back-speciﬁc function1
Self-rated health-related quality of life1

Intervention, number,
central tendency
(variability)

Control, number,
central tendency
(variability)

All participants,
number, central
tendency (variability)

n = xx
xx (xx)
xx (xx%)
xx (xx)
xx (xx to xx)
xx (xx to xx)
xx (xx%)
xx (xx%)

n = xx
xx (xx)
xx (xx%)
xx (xx)
xx (xx to xx)
xx (xx to xx)
xx (xx%)
xx (xx%)

n = xx
xx (xx)
xx (xx%)
xx (xx)
xx (xx to xx)
xx (xx to xx)
xx (xx%)
xx (xx%)

xx
xx
xx
xx
xx
xx
xx
xx

xx
xx
xx
xx
xx
xx
xx
xx

xx
xx
xx
xx
xx
xx
xx
xx

(xx%)
(xx%)
(xx%)
(xx%)
(xx%)
(xx)
(xx)
(xx)

(xx%)
(xx%)
(xx%)
(xx%)
(xx%)
(xx)
(xx)
(xx)

(xx%)
(xx%)
(xx%)
(xx%)
(xx%)
(xx)
(xx)
(xx)

1: Number, mean, standard deviation 2: Number, percentage 3: Number, median, interquartile range.

gorical variable with 4 levels corresponding to the repeated
measures. We will specify an unconstrained correlation
structure as this is most plausible, given the repeated measurements are at different time intervals. The model will
include three ﬁxed-effect terms for the group by time interactions and a random intercept. The random intercept will
account for the dependency of observations within participants due to repeated measures. The model is

rienced them (Supplemental Material Table A2). We will
calculate the proportion of participants that experienced
any adverse effect or any serious adverse effect and compare these proportions using a Chi2 Test, or Fisher’s Exact
test where appropriate (Table 3). We will compare the mean
group scores for the CEQ at baseline and at 2-wks postrandomization using an independent samples t-test.

y(ij) = ˇ0i + ˇ1.group + ˇ2.t1 + ˇ3.t2 + ˇ4.t3

Estimating treatment effect with incomplete
adherence

+ ˇ5.t1.group + ˇ6.t2.group + ˇ7.t3.group
where y(ij) is the outcome for the i’th participant at the j’th
time point, ˇ0i is the intercept for the i’th participant, modelled as a random effect, ∼N(ˇ 0i, var(ˇ0)), and t1, t2, t3 are
indicator variables for the three post-randomization timepoints. Baseline is the reference time.
The primary analysis will use the point estimate of ˇ5
and its 95% conﬁdence interval to estimate the effect of
intervention at 18-weeks post-randomization (Table 2).
Secondary outcomes
We will also use mixed-effects models to estimate the effect
of allocation to intervention group on function, QoL, adverse
effects, serious adverse effects and GPE. These models
will be speciﬁed similarly to the primary outcome. We will
use appropriate coefﬁcients and their 95% conﬁdence intervals to estimate the effects of intervention at 18, 26, and
52-weeks post-randomization (Table 3). We will calculate
the proportion of participants in each group that meet
the deﬁnition of recovery and compare these proportions
using a Chi2 Test, or Fisher’s Exact test where appropriate (Table 3). We will display lists of all adverse effects
and serious adverse effects reported throughout the trial
period (0−52 wks: available data for each participant) and
the proportion of participants in either group that expe-

If there is signiﬁcant non-adherence with the allocated
interventions we will estimate the complier-average causal
effect (CACE) using instrumental variable estimation.58---60
We will also estimate the average treatment effect in the
treated (ATET) using propensity score weighting.61,62
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Table 2

Analysis of primary outcome (shell).

Time point

Intervention,
number, mean (SD)

Control, number,
mean (SD)

Mean difference
(95% CI)

P Value

Pain intensity at
18 wksa
26 wks
52 wks
Overall intervention effectb

n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

a, b: P values are from a mixed effects model comparing between group differences at 18-weeks post-randomization (a: primary outcome)
and over the entire 52-week trial (b).

Table 3

Analysis of secondary outcomes (shell).

Time point

Intervention, number,
central tendency
(variability)

Control, number,
central tendency
(variability)

Effect measure
(95% CI)

P Value

Back-speciﬁc functiona at
18 wks
26 wks
52 wks
Overall intervention effectb
Self-rated health-related QoLc at
18 wks
26 wks
52 wks
Overall intervention effectb
Recoveryd at
26 wks
Adverse effects during interventione
18 wks
Adverse effects throughout trialf
18 wks
26 wks
52 wks
Overall intervention effectb
Serious adverse effects during interventiong
18 wks
Serious adverse effects throughout trialh
18 wks
26 wks
52 wks
Overall intervention effectb
Global perceived effecti at
18 wks
26 wks
52 wks
Overall intervention effectb

n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

n = xx
xx (xx)
n = xx
xx (xx)
n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
n = xx
xx (xx)
n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)

.xx

xx (xx to xx)

.xx

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

n = xx
xx (xx)
n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)

.xx

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

n = xx
xx (xx)
xx (xx)
xx (xx)

n = xx
xx (xx)
xx (xx)
xx (xx)

xx (xx to xx)
xx (xx to xx)
xx (xx to xx)

.xx
.xx
.xx
.xx

a

Roland-Morris Disability Questionnaire.
P Value is from a mixed effects model, comparing between-group differences over the entire 52-week trial.
c Health-related quality of life.
d A participant is considered recovered when the outcome score for pain intensity (in the past week) is either 0 or 1 on the 11-point
NRS at both 18- and 26-weeks.
e Sum of any adverse effects during intervention period.
f Any adverse effects over the entire 52-week trial.
g Sum of any serious adverse effects during intervention period.
h Any serious adverse effects over the entire 52-week trial.
i Global Back Recovery Scale.
b
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